Drug Type Small molecule drug |
Synonyms AD-16, GIBH-130 |
Target- |
Mechanism Neuritis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20N6O |
InChIKeyZTJHTEHADIHZJS-UHFFFAOYSA-N |
CAS Registry1252608-59-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 1 | CN | 10 Aug 2022 | |
Cognition Disorders | Phase 1 | CN | 28 Jan 2019 | |
Cognition Disorders | Phase 1 | CN | 28 Jan 2019 | |
Memory Disorders | Phase 1 | CN | 28 Jan 2019 | |
Memory Disorders | Phase 1 | CN | 28 Jan 2019 | |
Mild dementia | Phase 1 | CN | 28 Jan 2019 | |
Mild dementia | Phase 1 | CN | 28 Jan 2019 | |
Moderate dementia | Phase 1 | CN | 28 Jan 2019 | |
Moderate dementia | Phase 1 | CN | 28 Jan 2019 |